세계의 건선 치료 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Psoriasis Treatment Market was valued at USD 28.1 billion in 2024 and is estimated to grow at a CAGR of 9.4% to reach USD 68.4 billion by 2034.

The upward trend is fueled by the growing incidence of autoimmune skin diseases and chronic inflammatory disorders worldwide. Increased awareness among both healthcare providers and patients, coupled with the continuous development of next-generation biologics and targeted small-molecule drugs, continues to push the market forward. Emerging innovations in personalized treatment approaches and advanced drug delivery technologies are also playing a major role in accelerating market growth. As the burden of chronic skin conditions grows, the demand for effective, accessible, and sustainable treatment options is expanding rapidly. The industry continues to evolve with a diverse pipeline of therapies that focus on improving patient outcomes, minimizing flare-ups, and enhancing overall quality of life. The rise in demand for personalized healthcare solutions and greater R&D activity across the pharmaceutical sector are also contributing to the ongoing expansion of this market.

Plaque psoriasis and psoriatic arthritis represent the most prevalent manifestations of the disease, with many patients experiencing joint discomfort that increases the demand for systemic treatment approaches. The psoriasis treatment market falls within the dermatology and immunology sectors, focusing on managing this long-term immune-driven skin disorder marked by inflamed, scaly lesions and systemic symptoms. A broad portfolio of therapeutic choices defines the space, ranging from topical solutions like corticosteroids and vitamin D analogs to oral agents and injectable biologics such as IL-17, TNF-a, and IL-23 inhibitors, including biosimilars designed for cost-effective treatment access.

In 2024, the corticosteroids segment accounted for a 37.4% share due to their targeted mechanism and well-established clinical outcomes. This segment is forecasted to reach USD 25.2 billion by 2034, at a CAGR of 9.2%. Their widespread use stems from affordability, consistent effectiveness, and rapid symptom relief. Corticosteroids remain a go-to solution for mild to moderate disease severity, particularly in outpatient care settings, thanks to their dual anti-inflammatory and immune-modulating properties.

The topical therapies segment generated USD 15.6 billion in 2024, driven by their ease of use and lower risk of systemic side effects. They remain the first line of defense for individuals with milder symptoms, often prescribed at the onset of treatment or for long-term disease management. These formulations, available in forms like creams, foams, and gels, offer cost-effective and user-friendly administration, making them highly favorable for routine application in everyday settings.

North America Psoriasis Treatment Market held 41.1% share in 2024. The regional growth is propelled by increasing case numbers and robust financial backing for research-driven product development. A solid healthcare framework supports early-stage disease detection and timely intervention across countries within the region. The presence of major pharmaceutical manufacturers has spurred innovation in dermatological medications, biosimilar launches, and oral therapeutic options. At the same time, beneficial insurance policies and public health campaigns are improving patient access to advanced treatment solutions.

Key players influencing the Psoriasis Treatment Market include Johnson & Johnson, Pfizer, Merck & Co., Biogen, AbbVie, Eli Lilly, Biocon, LEO Pharma, Amgen, Novartis, UCB Pharma, Arcutis Biotherapeutics, Boehringer Ingelheim, Sun Pharmaceutical, and Bristol-Myers Squibb. These companies continue to lead innovation, clinical trials, and therapeutic advancements within the market. Companies operating in the Psoriasis Treatment Market are adopting multiple strategies to expand their footprint and competitive edge. Key efforts include prioritizing R&D to develop biologics and small-molecule drugs with higher efficacy and reduced side effects. Many firms are actively expanding their drug pipelines with next-gen treatments targeting IL and TNF pathways. Strategic partnerships, acquisitions, and licensing deals are also being pursued to accelerate innovation and enter new regional markets. A growing focus is placed on biosimilars to enhance affordability and treatment accessibility.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 3600 synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Drug class trends
  • 2.2.3 Type trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of psoriasis
    • 3.2.1.2 Demographic shifts and hereditary risk factors
    • 3.2.1.3 Emergence of next-generation therapies
    • 3.2.1.4 Heightened focus on systemic inflammation and comorbidities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Treatment-related complications and resistance
    • 3.2.2.2 Healthcare disparities in underserved regions
  • 3.2.3 Market opportunities
    • 3.2.3.1 Innovation in targeted and combination regimens
    • 3.2.3.2 Growth in precision dermatology and digital health
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Future market trends
• 3.6 Investment and funding landscape
• 3.7 Pipeline analysis
• 3.8 Pricing analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Interleukins inhibitors
  • 5.2.1 Secukinumab
  • 5.2.2 Ustekinumab
  • 5.2.3 Other interleukin inhibitors
• 5.3 TNF inhibitors
  • 5.3.1 Etanercept
  • 5.3.2 Certolizumab pegol
  • 5.3.3 Adalimumab
  • 5.3.4 Infliximab
  • 5.3.5 Golimumab
• 5.4 Vitamin D analogs
  • 5.4.1 Calcitriol
  • 5.4.2 Calcipotriol
  • 5.4.3 Tacalcitol
• 5.5 Corticosteroids
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Psoriatic arthritis
• 6.3 Plaque psoriasis
• 6.4 Inverse psoriasis
• 6.5 Other types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AbbVie
• 10.2 Amgen
• 10.3 Arcutis Biotherapeutics
• 10.4 Biocon
• 10.5 Biogen
• 10.6 Boehringer Ingelheim
• 10.7 Bristol-Myers Squibb
• 10.8 Eli Lilly
• 10.9 Johnson & Johnson
• 10.10 LEO Pharma
• 10.11 Merck & Co.
• 10.12 Novartis
• 10.13 Pfizer
• 10.14 Sun Pharmaceutical
• 10.15 UCB Pharma